Judge: Nevada pharmacy board cannot regulate cannabis, must remove from Schedule 1 drug list - The Nevada Independent
A Nevada judge ruled that the state pharmacy board cannot regulate cannabis and must remove it from Schedule 1, potentially easing state-level restrictions but not affecting federal FDA/DEA oversight for pharmaceutical manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical manufacturers operating in Nevada or considering cannabis-related products should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; monitor state regulatory updates.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Nevada pharmacy board loses authority over cannabis; cannabis removed from state Schedule 1, but federal scheduling unchanged.
Who it affects
Pharmaceutical manufacturers operating in Nevada or considering cannabis-related products
What you must do
Monitor for any changes in state licensing or compliance requirements; no immediate action needed for federal compliance.
Deadline
No immediate deadline; monitor state regulatory updates.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines